Twist Bioscience Corp vs Uber Technologies Inc — how do they compare? Twist Bioscience Corp trades at $161.72 (market cap $10.08B), while Uber Technologies Inc trades at $71.23 (market cap $143.47B). The key difference: Uber Technologies Inc is far larger — about 14.2× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Uber Technologies Inc for 88 Days on average.
| TWST | UBER | |
|---|---|---|
Market Cap | $10.08B | $143.47B |
Volume | 4,229,037 | 14,430,657 |
Sector | Health | Technology |
52-Week High | $205.00 | $99.72 |
52-Week Low | $25.45 | $65.94 |
Typical Hold Time | 27 Days | 88 Days |
Enterprise Value | $10.01B | $152.81B |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Uber trades at $68.45, down 0.91% on the day, with a bearish technical signal despite strong fundamentals. The company reported $52.02B revenue in 2025 with $10.05B net income, maintaining robust growth from $44.0B revenue in 2024. Recent expansion includes the Costco delivery partnership reaching 47 states, while CEO Dara Khosrowshahi purchased $10 million in shares, signaling confidence.
Uber presents a compelling growth story with expanding profitability and dominant market position, though technical indicators suggest near-term pressure. The consensus price target of $104.72 implies 53% upside, supported by 82.5% analyst buy ratings. Key risks include robotaxi competition and projected negative cash flow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →